The estimated Net Worth of Lutz Lingnau is at least $850 Tisíc dollars as of 27 September 2019. Lutz Lingnau owns over 3,000 units of Nektar Therapeutics stock worth over $33,375 and over the last 17 years Lutz sold NKTR stock worth over $816,540.
Lutz has made over 15 trades of the Nektar Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently Lutz sold 3,000 units of NKTR stock worth $53,520 on 27 September 2019.
The largest trade Lutz's ever made was exercising 30,000 units of Nektar Therapeutics stock on 5 April 2018 worth over $277,200. On average, Lutz trades about 7,167 units every 54 days since 2007. As of 27 September 2019 Lutz still owns at least 26,700 units of Nektar Therapeutics stock.
You can see the complete history of Lutz Lingnau stock trades at the bottom of the page.
Lutz's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158.
Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie a John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Nektar Therapeutics executives and other stock owners filed with the SEC include: